Literature DB >> 10451689

Pulmonary hypertension: its assessment and treatment.

S Brij1, A J Peacock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10451689      PMCID： PMC1765930          DOI： 10.1136/thx.54.2008.s28

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  24 in total

1.  Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis with pulmonary hypertension.

Authors:  G Rolla; P Colagrande; L Brussino; C Bucca; M T Bertero; F Caligaris-Cappio
Journal:  Lancet       Date:  1998-05-16       Impact factor: 79.321

2.  Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchange.

Authors:  P Jolliet; P Bulpa; J B Thorens; M Ritz; J C Chevrolet
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

Review 3.  Properties and regulation of guanylate cyclase and some proposed functions for cyclic GMP.

Authors:  F Murad; W P Arnold; C K Mittal; J M Braughler
Journal:  Adv Cyclic Nucleotide Res       Date:  1979

4.  Fatal outcome following nifedipine for pulmonary hypertension.

Authors:  H W Farber; J B Karlinsky; L J Faling
Journal:  Chest       Date:  1983-04       Impact factor: 9.410

5.  An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension.

Authors:  G Mikhail; J Gibbs; M Richardson; G Wright; A Khaghani; N Banner; M Yacoub
Journal:  Eur Heart J       Date:  1997-09       Impact factor: 29.983

6.  Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

Authors:  V V McLaughlin; D E Genthner; M M Panella; S Rich
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

7.  Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension.

Authors:  L J Rubin; B M Groves; J T Reeves; M Frosolono; F Handel; A E Cato
Journal:  Circulation       Date:  1982-08       Impact factor: 29.690

8.  Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.

Authors:  O Sitbon; M Humbert; J L Jagot; O Taravella; M Fartoukh; F Parent; P Herve; G Simonneau
Journal:  Eur Respir J       Date:  1998-08       Impact factor: 16.671

9.  A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension.

Authors:  I M Robbins; B W Christman; J H Newman; R Matlock; J E Loyd
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

10.  Association between cyclic GMP accumulation and acetylcholine-elicited relaxation of bovine intrapulmonary artery.

Authors:  L J Ignarro; T M Burke; K S Wood; M S Wolin; P J Kadowitz
Journal:  J Pharmacol Exp Ther       Date:  1984-03       Impact factor: 4.030
View more
  2 in total

Review 1.  Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension.

Authors:  Ezequiel Balmori Melian; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Beraprost sodium for chronic diabetic foot ulcer: a randomized controlled trial in thammasat university hospital.

Authors:  Surajit Awsakulsutthi; Kwanjit Punpho; Jinpitcha Mamom; Pairat Baikrut; Patcharee Yingchoorod
Journal:  Ann Vasc Dis       Date:  2014-02-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.